Sprint Bioscience AB (OSTO:SPRINT) Cyclically Adjusted FCF per Share: kr-1.38 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr3.86
GF Value kr2.18
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Cyclically Adjusted FCF per Share?

Sprint Bioscience AB OSTO:SPRINT +1.58% 32 Cyclically Adjusted FCF per Share is kr-1.38 as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sprint Bioscience AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.183. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-1.38 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-13), Sprint Bioscience AB's current stock price is kr3.86. Sprint Bioscience AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-1.38. Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF of today is .


Sprint Bioscience AB  (OSTO:SPRINT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sprint Bioscience AB Cyclically Adjusted FCF per Share Related Terms


Sprint Bioscience AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Cyclically Adjusted FCF per Share Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1.81 -1.62 -1.47

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -1.48 -1.69 -1.47 -1.38

OSTO:SPRINT vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sprint Bioscience AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.183/133.5600*133.5600
=-0.183

Current CPI (Mar. 2026) = 133.5600.

Sprint Bioscience AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.673 101.019 -0.890
201609 2.050 101.138 2.707
201612 -0.903 102.022 -1.182
201703 -0.950 102.022 -1.244
201706 -0.771 102.752 -1.002
201709 -0.469 103.279 -0.607
201712 -0.961 103.793 -1.237
201803 0.790 103.962 1.015
201806 -0.993 104.875 -1.265
201809 -1.037 105.679 -1.311
201812 -0.861 105.912 -1.086
201903 -1.060 105.886 -1.337
201906 -0.781 106.742 -0.977
201909 0.462 107.214 0.576
201912 -0.750 107.766 -0.930
202003 0.114 106.563 0.143
202006 -0.936 107.498 -1.163
202009 -0.557 107.635 -0.691
202012 -0.528 108.296 -0.651
202103 -0.529 108.360 -0.652
202106 -1.012 108.928 -1.241
202109 0.372 110.338 0.450
202112 -0.338 112.486 -0.401
202203 -0.287 114.825 -0.334
202206 -0.326 118.384 -0.368
202209 -0.309 122.296 -0.337
202212 0.000 126.365 0.000
202303 -0.032 127.042 -0.034
202306 -0.166 129.407 -0.171
202309 0.557 130.224 0.571
202312 -0.038 131.912 -0.038
202403 -0.141 132.205 -0.142
202406 -0.052 132.716 -0.052
202409 -0.060 132.304 -0.061
202412 -0.094 132.987 -0.094
202503 -0.078 132.825 -0.078
202506 -0.137 133.699 -0.137
202509 -0.132 133.480 -0.132
202512 1.098 133.390 1.099
202603 -0.183 133.560 -0.183

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-1.38 mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Cyclically Adjusted FCF per Share of kr-1.38 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Cyclically Adjusted FCF per Share too high?
Sprint Bioscience AB's current Cyclically Adjusted FCF per Share is kr-1.38. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Sprint Bioscience AB's Cyclically Adjusted FCF per Share of kr-1.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Cyclically Adjusted FCF per Share is kr-1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr3.86 — trading 77.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-1.38. Sprint Bioscience AB's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Cyclically Adjusted FCF per Share is kr-1.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr3.86 is trading 77.1% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Cyclically Adjusted FCF per Share: kr-1.38
  • GF Value™: kr2.18 vs. price of kr3.86 (77.1% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.86
Price
kr2.18
GF Value